Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very different. While Celgene is racking up substantial growth for its top-selling medicines, Gilead Sciences is navigating an increasingly competitive market for its hepatitis C drugs. Are these companies on the right track?
In this episode of the Motley Fool's Industry Focus: Healthcare podcast, Foolish investors Kristine Harjes and Todd Campbell discuss the companies' second-quarter earnings results and what's next for these two big-cap biotech stocks.
Also, Kristine and Todd weigh in on the rapidly evolving market for non-small cell lung cancer treatment, providing insight into the latest quarterly performance for Merck & Co.'s (NYSE: MRK) Keytruda and Bristol-Myers Squibb's (NYSE: BMY) Opdivo.
Source: Fool.com
Merck & Co. Inc. Stock
With 28 Buy predictions and 1 Sell predictions Merck & Co. Inc. is one of the favorites of our community.
With a target price of 124 € there is a slightly positive potential of 4.38% for Merck & Co. Inc. compared to the current price of 118.8 €.